Category: Clinical Research/Diagn.
PerkinElmer to Acquire In-Vitro Diagnostics Company Immunodiagnostic Systems Holdings PLC
Endocrinology testing specialist expands PerkinElmer’s immunodiagnostics segment WALTHAM, Mass.–(BUSINESS WIRE)–May 17, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Immunodiagnostic Systems Holdings PLC (LSE: IHS) (“IDS”) are pleased to announce that they have reached an agreement on the terms of a recommended all cash offer whereby PerkinElmer will acquire IDS for approximately $155 million (£110 Million).... Read more
Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer
Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancer Studies in personalised healthcare exploring tumour agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualised treatment plans New data, and drug combination strategies for the treatment of lymphoma from the largest... Read more
Bio-Techne and 908 Devices Announce Joint Collaboration
MAY 04, 2021 MINNEAPOLIS and BOSTON, May 4, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) today announced a joint collaboration to develop an extended workflow solution for protein characterization. Bio-Techne, a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, and owner of the leading ProteinSimple... Read more
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
About 90,000 women globally die from endometrial cancer each year1 VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly) Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a... Read more
Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Kartos Therapeutics, Inc. are pleased to announce a new partnership to co-develop a TP53 companion diagnostic (CDx) based on the content of Illumina’s comprehensive genomic profiling assay, TruSight™ Oncology 500 (TSO 500). This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with... Read more
Roche purchases shares in tender offer for GenMark Diagnostics, Inc.
Basel, 22 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics, Inc. today announced that Roche’s wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK)... Read more
Agilent Completes Acquisition of Resolution Bioscience, Expands Role in Fast-growing NGS Market for Precision Oncology
SANTA CLARA, Calif., April 15, 2021 Agilent Technologies, Inc. (NYSE: A) today announced it has completed the acquisition of Resolution Bioscience, a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions. Resolution Bioscience complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further... Read more
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization
Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization – Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry – Adds highly complementary services for the company’s fastest growing end market – Offers both meaningful cost and revenue synergies which will further accelerate growth... Read more
Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development
MINNEAPOLIS, April 14, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline. Bio-Techne is a global life sciences company providing... Read more